• 1
    Schmidt AM, Vianna M, Gerlach M et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 267: 1498714997.
  • 2
    Miyata T, Hori O, Zhang J et al. The receptor for advanced glycation endproducts (RAGE) mediates the interaction of AGE-b2 microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implications for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996; 98: 10881094.
  • 3
    Yan SS, Wu ZY, Zhang HP et al. Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 2003; 9: 287293.
  • 4
    Chen Y, Yan SS, Colgan J et al. Blockade of late stages of autoimmune diabetes by inhibition of the receptor for advanced glycation end products. J Immunol 2004; 173: 13991405.
  • 5
    Cataldegirmen G, Zeng S, Feirt N et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005; 201: 473484.
  • 6
    Kislinger T, Fu C, Huber B et al. Ne (carboxymethyl)lysine modifications of proteins are ligands for RAGE that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 3174031749.
  • 7
    Hori O, Brett J, Slattery T et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 2575225761.
  • 8
    Taguchi A, Blood DC, Del Toro G et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354360.
  • 9
    Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889901.
  • 10
    Chavakis T, Bierhaus A, Al-Fakhri N et al. The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 2003; 198: 15071515.
  • 11
    Hofmann MA, Drury S, Hudson BI et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123135.
  • 12
    Liliensiek B, Weigand MA, Bierhaus A et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 16411650.
  • 13
    Kerjaschki D, Regele HM, Moosberger I et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004; 15: 603612.
  • 14
    Dumitriu IE, Baruah P, Valentinis B et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 75067515.
  • 15
    Neeper M, Schmidt AM, Brett J et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 1499815004.
  • 16
    Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 10251031.
  • 17
    Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343350.
  • 18
    Ebihara T, Endo R, Kikuta H et al. Differential gene expression of S100 protein family in leukocytes from patients with Kawasaki disease. Eur J Pediatr 2005; 164: 427431.
  • 19
    Webb M, Emberley ED, Lizardo M et al. Expression analysis of the mouse S100A7/psoriasin gene in skin inflammation and mammary tumorigenesis. BMC Cancer 2005; 5: 17.
  • 20
    Foell D, Kucharzik T, Kraft M et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003; 52: 847853.
  • 21
    Foell D, Seeliger S, Vogl T et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003; 58: 613617.
  • 22
    Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004; 50: 37623771.
  • 23
    Frosch M, Vogl T, Waldherr R, Sorg C, Sunderkotter C, Roth J. Expression of MRP8 and MRP14 by macrophages is a marker for severe forms of glomerulonephritis. J Leukoc Biol 2004; 75: 198206.
  • 24
    Sorci G, Riuzzi F, Agneletti AL, Marchetti C, Donato R. S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner. Mol Cell Biol 2003; 23: 48704881.
  • 25
    Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248251.
  • 26
    Zamora R, Grishin A, Wong C et al. High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am J Physiol Gastrointest Liver Physiol 2005; 289: G643G652.
  • 27
    Lin X, Yang H, Sakuragi T et al. Alpha-chemokine receptor blockade reduces high mobility group box 1 protein-induced lung inflammation and injury and improves survival in sepsis. Am J Physiol Lung Cell Mol Physiol 2005; 289: L583L590.
  • 28
    Tsung A, Sahai R, Tanaka H et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201: 11351143.
  • 29
    Andersson U, Tracey KJ. HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am 2004; 30: 627637, xi.
  • 30
    Kokkola R, Andersson A, Mullins G et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol 2005; 61: 19.
  • 31
    Park JS, Svetkauskaite D, He Q et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 73707377.
  • 32
    Bucciarelli LG, Kaneko M, Anathakrishnan R et al. Receptor for advanced glycation endproducts: key modulator of myocardial ischemic injury. Circulation 2006; 113: 12261234.
  • 33
    Barile GR, Pachydaki SI, Tari SR et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005; 46: 29162924.
  • 34
    Flechner SM, Feng J, Mastroianni B et al. The effect of 2-gram versus 1-gram concentration controlled mycophenolate mofetil on renal transplant outcomes using sirolimus-based calcineurin inhibitor drug-free immunosuppression. Transplantation 2005; 79: 926934.
  • 35
    Hafiz MM, Faradji RN, Froud T et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 2005; 80: 17181728.